• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued?

    Simply Wall St·07/18/2026 22:23:23
    Listen to the news

    ADMIRE Milestone and Why It Matters for Alpha Tau Medical Stock

    Alpha Tau Medical (NasdaqCM:DRTS) drew fresh attention after reporting the first successful treatment of an immunocompromised patient in its ADMIRE clinical study for recurrent cutaneous squamous cell carcinoma using Alpha DaRT.

    This marks a key clinical milestone for a vulnerable cancer population that often has limited treatment options, giving investors new information to weigh around the company’s technology focus and long-term oncology ambitions.

    See our latest analysis for Alpha Tau Medical.

    That clinical update landed as Alpha Tau Medical’s share price moved to $13.55, with a 1-month share price return of 41.0% and year-to-date share price return of 180.54%, alongside a 1-year total shareholder return of 345.72%. These figures suggest strong recent momentum.

    If breakthroughs in cancer treatment are on your radar, this could be a good moment to broaden your watchlist and check out 39 healthcare AI stocks

    After Alpha Tau Medical’s sharp move, and with the stock now sitting only around 5% below the average analyst price target, is the market being too cautious about a loss making, pre revenue cancer platform, or not cautious enough?

    Preferred Price-to-Book Multiple of 17.6x for Alpha Tau Medical: Is It Justified?

    With Alpha Tau Medical last closing at $13.55 and trading on a P/B of 17.6x, the stock is priced far above both peers and its wider industry on this yardstick.

    The price to book ratio compares the company’s market value to its net assets on the balance sheet. It is often used for asset heavy or early stage healthcare companies where earnings are not yet meaningful. For Alpha Tau Medical, this means investors are currently paying 17.6 times the company’s book value for each share, despite the business reporting a loss of $56.875m and no revenue.

    Compared with similar companies, Alpha Tau Medical looks expensive on this metric. The P/B of 17.6x is more than three times the 4.9x average of peers and also sits far above the 2.4x average for the US Medical Equipment industry. That gap suggests the market is assigning a much richer valuation to Alpha Tau Medical’s pipeline and technology than it is to most listed peers, and the multiple would need to compress significantly to line up with sector averages.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 17.6x (OVERVALUED)

    However, Alpha Tau Medical still faces meaningful risks, including its loss of $56.875m with no revenue and its reliance on positive trial progress to support its rich P/B multiple.

    Find out about the key risks to this Alpha Tau Medical narrative.

    Next Steps

    With such contrasting signals around Alpha Tau Medical, it makes sense to move quickly and check the underlying data for yourself. You can then weigh up the company’s 1 key reward and 4 important warning signs using 1 key reward and 4 important warning signs

    Looking for more investment ideas beyond Alpha Tau Medical?

    If you are serious about building a stronger portfolio, do not stop with Alpha Tau Medical. Put a few minutes into scanning other opportunities that match your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.